Autoantigen BiP-derived HLA-DR4 epitopes differentially recognized by effector and regulatory T cells in rheumatoid arthritis

Arthritis and Rheumatology

Volumn 67, Issue 5, 2015, Pages 1171-1181

  Shoda, Hirofumi ^a   Fujio, Keishi ^a   Sakurai, Keiichi ^a   Ishigaki, Kazuyoshi ^a   Nagafuchi, Yasuo ^a   Shibuya, Mihoko ^a   Sumitomo, Shuji ^a   Okamura, Tomohisa ^a   Yamamoto, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; BLOCKING ANTIBODY; C REACTIVE PROTEIN; EPITOPE; GAMMA INTERFERON; GLUCOSE REGULATED PROTEIN 78; GLUCOSE REGULATED PROTEIN 78 336-355; HLA DR4 ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 17; NEUROPILIN 1; PEPTIDE DERIVATIVE; T LYMPHOCYTE RECEPTOR; UNCLASSIFIED DRUG; AUTACOID; BAX-INHIBITING PEPTIDE, BIP; CYTOKINE; IL10 PROTEIN, HUMAN; OLIGOPEPTIDE; PEPTIDE FRAGMENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIGEN RECOGNITION; ARTHRITIS; ARTICLE; BINDING ASSAY; CD4+ CD25+ FOXP3+ REGULATORY T LYMPHOCYTE; CD4+ FOXP3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL DISEASE ACTIVITY INDEX; CONTROLLED STUDY; CYTOKINE RELEASE; DAS28; DISEASE ACTIVITY; DISEASE COURSE; DISEASE SEVERITY; EFFECTOR CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; GEL FILTRATION; HUMAN; HUMAN CELL; IC50; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; THERAPY EFFECT; ANIMAL; CASE CONTROL STUDY; CELL PROLIFERATION; EXPERIMENTAL ARTHRITIS; IMMUNOLOGY; MONONUCLEAR CELL; SECRETION (PROCESS); SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; AUTOANTIGENS; CASE-CONTROL STUDIES; CELL PROLIFERATION; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; HLA-DR4 ANTIGEN; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-10; LEUKOCYTES, MONONUCLEAR; LUPUS ERYTHEMATOSUS, SYSTEMIC; MICE; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84928596319     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.39054     Document Type: Article

References (41)

1. Littman DR, Rudensky AY., Th17 and regulatory T cells in mediating and restraining inflammation. Cell 2010; 140: 845-58.
2. Yamamoto K, Sakoda H, Nakajima T, Kato T, Okubo M, Dohi M, et al. Accumulation of multiple T cell clonotypes in the synovial lesions of patients with rheumatoid arthritis revealed by a novel clonality analysis. Int Immunol 1992; 4: 1219-23.
3. Kotzin BL, Kappler J., Targeting the T cell receptor in rheumatoid arthritis [editorial]. Arthritis Rheum 1998; 41: 1906-10.
4. Stastny P., Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med 1978; 298: 869-71.
5. Kochi Y, Okada Y, Suzuki A, Ikari K, Terao C, Takahashi A, et al. A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nat Genet 2010; 42: 515-9.
6. Gregersen PK, Silver J, Winchester RJ., The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30: 1205-13.
7. Kotzin BL, Falta MT, Crawford F, Rosloniec EF, Bill J, Marrack P, et al. Use of soluble peptide-DR4 tetramers to detect synovial T cells specific for cartilage antigens in patients with rheumatoid arthritis. Proc Natl Acad Sci U S A 2000; 97: 291-6.
8. Falta MT, Fontenot AP, Rosloniec EF, Crawford F, Roark CL, Bill J, et al. Class II major histocompatibility complex-peptide tetramer staining in relation to functional avidity and T cell receptor diversity in the mouse CD4+ T cell response to a rheumatoid arthritis-associated antigen. Arthritis Rheum 2005; 52: 1885-96.
9. Von Delwig A, Locke J, Robinson JH, Ng WF., Response of Th17 cells to a citrullinated arthritogenic aggrecan peptide in patients with rheumatoid arthritis. Arthritis Rheum 2010; 62: 143-9.
10. Snir O, Rieck M, Gebe JA, Yue BB, Rawlings CA, Nepom G, et al. Identification and functional characterization of T cells reactive to citrullinated vimentin in HLA-DRB1∗0401-positive humanized mice and rheumatoid arthritis patients. Arthritis Rheum 2011; 63: 2873-83.
11. Yoo SA, You S, Yoon HJ, Kim DH, Kim HS, Lee K, et al. A novel pathogenic role of the ER chaperone GRP78/BiP in rheumatoid arthritis. J Exp Med 2012; 209: 871-86.
12. Blass S, Union A, Raymackers J, Schumann F, Ungethum U, Muller-Steinbach S, et al. The stress protein BiP is overexpressed and is a major B and T cell target in rheumatoid arthritis. Arthritis Rheum 2001; 44: 761-71.
13. Corrigall VM, Bodman-Smith MD, Fife MS, Canas B, Myers LK, Wooley P, et al. The human endoplasmic reticulum molecular chaperone BiP is an autoantigen for rheumatoid arthritis and prevents the induction of experimental arthritis. J Immunol 2001; 166: 1492-8.
14. Lu MC, Lai NS, Yu HC, Huang HB, Hsieh SC, Yu CL., Anti-citrullinated protein antibodies bind surface-expressed citrullinated Grp78 on monocyte/macrophages and stimulate tumor necrosis factor α production. Arthritis Rheum 2010; 62: 1213-23.
15. Shoda H, Fujio K, Shibuya M, Okamura T, Sumitomo S, Okamoto A, et al. Detection of autoantibodies to citrullinated BiP in rheumatoid arthritis patients and pro-inflammatory role of citrullinated BiP in collagen-induced arthritis. Arthritis Res Ther 2011; 13: R191.
16. Bodman-Smith MD, Corrigall VM, Kemeny DM, Panayi GS., BiP, a putative autoantigen in rheumatoid arthritis, stimulates IL-10-producing CD8-positive T cells from normal individuals. Rheumatology (Oxford) 2003; 42: 637-44.
17. Brownlie RJ, Myers LK, Wooley PH, Corrigall VM, Bodman-Smith MD, Panayi GS, et al. Treatment of murine collagen-induced arthritis by the stress protein BiP via interleukin-4-producing regulatory T cells: a novel function for an ancient protein. Arthritis Rheum 2006; 54: 854-63.
18. Yoshida K, Ochiai A, Matsuno H, Panayi GS, Corrigall VM., Binding immunoglobulin protein resolves rheumatoid synovitis: a xenogeneic study using rheumatoid arthritis synovial membrane transplants in SCID mice. Arthritis Res Ther 2011; 13: R149.
19. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569-81.
20. Hochberg MC, for the Diagnostic and Therapeutic Criteria Committee of the American College of Rheumatology. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997; 40: 1725.
21. Kawai S, Maekawajiri S, Tokunaga K, Kashiwase K, Miyamoto M, Akaza T, et al. Routine low and high resolution typing of the HLA-DRB gene using the PCR-MPH (microtitre plate hybridization) method. Eur J Immunogenet 1996; 23: 471-86.
22. Rosloniec EF, Whittington KB, Zaller DM, Kang AH., HLA-DR1 (DRB1∗0101) and DR4 (DRB1∗0401) use the same anchor residues for binding an immunodominant peptide derived from human type II collagen. J Immunol 2002; 168: 253-9.
23. Sato AK, Zarutskie JA, Rushe MM, Lomakin A, Natarajan SK, Sadegh-Nasseri S, et al. Determinants of the peptide-induced conformational change in the human class II major histocompatibility complex protein HLA-DR1. J Biol Chem 2000; 275: 2165-73.
24. Weber CK, Haslbeck M, Englbrecht M, Sehnert B, Mielenz D, Graef D, et al. Antibodies to the endoplasmic reticulum-resident chaperones calnexin, BiP and Grp94 in patients with rheumatoid arthritis and systemic lupus erythematosus. Rheumatology (Oxford) 2010; 49: 2255-63.
25. Hammer J, Bono E, Gallazzi F, Belunis C, Nagy Z, Sinigaglia F., Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J Exp Med 1994; 180: 2353-8.
26. Schuler MM, Nastke MD, Stevanovikc S,. SYFPEITHI: database for searching and T-cell epitope prediction. Methods Mol Biol 2007; 409: 75-93.
27. Nielsen M, Justesen S, Lund O, Lundegaard C, Buus S., NetMHCIIpan-2.0: improved pan-specific HLA-DR predictions using a novel concurrent alignment and weight optimization training procedure. Immunome Res 2010; 6: 9.
28. Faria AM, Weiner HL., Oral tolerance. Immunol Rev 2005; 206: 232-59.
29. Bayrak S, Holmdahl R, Travers P, Lauster R, Hesse M, Dolling R, et al. T cell response of I-Aq mice to self type II collagen: meshing of the binding motif of the I-Aq molecule with repetitive sequences results in autoreactivity to multiple epitopes. Int Immunol 1997; 9: 1687-99.
30. Hill JA, Southwood S, Sette A, Jevnikar AM, Bell DA, Cairns E., The conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1∗0401 MHC class II molecule. J Immunol 2003; 171: 538-41.
31. James EA, Moustakas AK, Bui J, Papadopoulos GK, Bondinas G, Buckner JH, et al. HLA-DR1001 presents "altered-self" peptides derived from joint-associated proteins by accepting citrulline in three of its binding pockets. Arthritis Rheum 2010; 62: 2909-18.
32. Hill JA, Bell DA, Brintnell W, Yue D, Wehrli B, Jevnikar AM, et al. Arthritis induced by posttranslationally modified (citrullinated) fibrinogen in DR4-IE transgenic mice. J Exp Med 2008; 205: 967-79.
33. Leipe J, Grunke M, Dechant C, Reindl C, Kerzendorf U, Schulze-Koops H, et al. Role of Th17 cells in human autoimmune arthritis. Arthritis Rheum 2010; 62: 2876-85.
34. Van Hamburg JP, Asmawidjaja PS, Davelaar N, Mus AM, Colin EM, Hazes JM, et al. Th17 cells, but not Th1 cells, from patients with early rheumatoid arthritis are potent inducers of matrix metalloproteinases and proinflammatory cytokines upon synovial fibroblast interaction, including autocrine interleukin-17A production. Arthritis Rheum 2011; 63: 73-83.
35. Ito Y, Usui T, Kobayashi S, Iguchi-Hashimoto M, Ito H, Yoshitomi H, et al. Gamma/delta T cells are the predominant source of interleukin-17 in affected joints in collagen-induced arthritis, but not in rheumatoid arthritis. Arthritis Rheum 2009; 60: 2294-303.
36. Dai Z, Turtle CJ, Booth GC, Ridell SR, Gooley TA, Stevens AM, et al. Normally occurring NKG2D+CD4+ T cells are immunosuppressive and inversely correlated with disease activity in juvenile-onset lupus. J Exp Med 2009; 206: 793-805.
37. Esensten JH, Wofsy D, Bluestone JA., Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol 2009; 5: 560-5.
38. Mijnheer G, Prakken BJ, van Wijk F., The effect of autoimmune arthritis treatment strategies on regulatory T-cell dynamics. Curr Opin Rheumatol 2013; 25: 260-7.
39. Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 2014; 506: 376-381.
40. McGovern JL, Nguyen DX, Notley CA, Mauri C, Isenberg DA, Ehrenstein MR., Th17 cells are restrained by Treg cells via the inhibition of interleukin-6 in patients with rheumatoid arthritis responding to anti-tumor necrosis factor antibody therapy. Arthritis Rheum 2012; 64: 3129-38.
41. Samson M, Audia S, Janikashvili N, Ciudad M, Trad M, Fraszczak J, et al. Inhibition of interleukin-6 function corrects Th17/Treg cell imbalance in patients with rheumatoid arthritis. Arthritis Rheum 2012; 64: 2499-503.